UMB Bank n.a. Sells 1,319 Shares of Kenvue Inc. (NYSE:KVUE)

UMB Bank n.a. trimmed its holdings in Kenvue Inc. (NYSE:KVUE) by 36.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,332 shares of the company’s stock after selling 1,319 shares during the period. UMB Bank n.a.’s holdings in Kenvue were worth $56,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of KVUE. Norges Bank bought a new position in Kenvue in the fourth quarter valued at $521,348,000. Starboard Value LP acquired a new stake in shares of Kenvue during the 4th quarter worth about $467,864,000. Franklin Resources Inc. boosted its holdings in shares of Kenvue by 61.5% during the fourth quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company’s stock worth $912,059,000 after acquiring an additional 16,269,721 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in Kenvue by 12.3% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company’s stock valued at $2,085,070,000 after buying an additional 10,682,003 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in Kenvue by 3.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company’s stock worth $5,249,665,000 after purchasing an additional 8,211,748 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Trading Down 2.7%

NYSE KVUE opened at $21.44 on Friday. The business has a fifty day simple moving average of $23.03 and a 200 day simple moving average of $22.50. The firm has a market capitalization of $41.14 billion, a P/E ratio of 40.46, a PEG ratio of 2.62 and a beta of 0.98. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $25.17.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. The firm had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.69 billion. During the same quarter in the prior year, the company earned $0.28 EPS. The business’s revenue for the quarter was down 3.9% on a year-over-year basis. On average, analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th were paid a $0.205 dividend. The ex-dividend date was Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.82%. Kenvue’s payout ratio is presently 149.09%.

Analysts Set New Price Targets

KVUE has been the subject of several recent analyst reports. Canaccord Genuity Group upped their price objective on shares of Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. Barclays lifted their target price on shares of Kenvue from $22.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Monday, May 12th. Evercore ISI began coverage on Kenvue in a research note on Monday, March 24th. They issued an “in-line” rating and a $25.00 price target for the company. Piper Sandler upped their price target on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research report on Monday, February 24th. Finally, Citigroup raised their price objective on shares of Kenvue from $22.00 to $24.50 and gave the stock a “neutral” rating in a research report on Friday, May 9th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and an average price target of $25.33.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.